Breaking! Akeso plummets 8% during trading! Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880) falls over 2.5% to set a new historical low
Complete. Here is the key summaryOn June 2, 2026, Akeso saw a sharp drop of 8% during the session, dragging down the Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880) by over 2.5% to a historic low. As of 9:44 AM that day, the ETF fell 2.34% to CNY 0.418, with a turnover rate of 3.13%. Although the index-weighted stocks Zai Lab, Hansoh Pharma, and Akeso saw slight increases, RemeGen and SKB BIO experienced significant declines. The latest size of the ETF reached CNY 2.569 billion, an increase of CNY 438 million compared to a month ago
As of June 2, 2026, 09:44, the Hong Kong Stock Connect Innovative Drug ETF Hwabao (520880) fell by 2.34%, with the latest price reported at 0.418 yuan and a turnover rate of 3.13%.
The Hong Kong Stock Connect Innovative Drug ETF Hwabao (520880) closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index. Among the index-weighted stocks, Zai Lab rose by 0.83%, Hansoh Pharma rose by 0.32%, Akeso rose by 0.09%, while RemeGen fell by 2.95%, SKB BIO fell by 2.43%, and BeiGene fell by 0.94%. The index aims to reflect the performance of Hong Kong-listed companies that can be traded through the Hong Kong Stock Connect and are related to the research, development, and production of innovative drugs. Base date: December 31, 2020. Base point: 3000.
Data shows that the latest scale of the Hong Kong Stock Connect Innovative Drug ETF Hwabao (520880) has reached 2.569 billion yuan, with the latest shares amounting to 5.948 billion shares, an increase of 438 million yuan in fund size compared to a month ago.
As of the previous trading day, the net inflow of main funds into the Hong Kong Stock Connect Innovative Drug ETF Hwabao (520880) was 11.6244 million yuan.
Hong Kong Stock Connect Innovative Drug ETF Hwabao (520880), off-exchange connection (025220.OF, 025221.OF)